Literature DB >> 8537683

Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.

D C Montefiori1, G Pantaleo, L M Fink, J T Zhou, J Y Zhou, M Bilska, G D Miralles, A S Fauci.   

Abstract

Serum antibodies from human immunodeficiency virus type 1 (HIV-1)-infected long-term non-progressors (LTNPs) and non-LTNPs were evaluated for virus neutralization and infection enhancement in vitro. Sera from LTNPs had higher average titers of neutralizing antibodies to HIV-1 strains IIIB and MN and more frequently neutralized primary isolates from progressors (14.9% vs. 1.3%, P = .002). Replication-competent HIV-1 was isolated from peripheral blood mononuclear cells and lymph nodes of 3 LTNPs. All viruses from LTNPs had a non-syncytium-inducing phenotype, were resistant to neutralization by autologous serum obtained at the time of virus isolation, and showed little evidence of a heightened sensitivity to neutralization by heterologous sera. Complement-mediated, antibody-dependent enhancement (C'-ADE) of HIV-1IIIB and primary isolates was equally prevalent for sera from LTNPs and non-LTNPs. Results indicate that LTNPs produce vigorous serum antibody responses and that long-term nonprogression is not associated with homologous neutralization or the absence of C'-ADE.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8537683     DOI: 10.1093/infdis/173.1.60

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  88 in total

1.  Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects.

Authors:  G M Ortiz; M Wellons; J Brancato; H T Vo; R L Zinn; D E Clarkson; K Van Loon; S Bonhoeffer; G D Miralles; D Montefiori; J A Bartlett; D F Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

2.  Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization.

Authors:  Bimal K Chakrabarti; Wing-pui Kong; Bei-yue Wu; Zhi-Yong Yang; Jacques Friborg; Xu Ling; Steven R King; David C Montefiori; Gary J Nabel
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

3.  Autologous neutralizing antibody to human immunodeficiency virus-1 and replication-competent virus recovered from CD4+ T-cell reservoirs in pediatric HIV-1-infected patients on HAART.

Authors:  Natascha Ching; Karin A Nielsen-Saines; Jaime G Deville; Lian S Wei; Eileen Garratty; Yvonne J Bryson
Journal:  AIDS Res Hum Retroviruses       Date:  2010-05       Impact factor: 2.205

4.  Dynamics of HIV-1 mRNA expression in patients with long-term nonprogressive HIV-1 infection.

Authors:  M Comar; C Simonelli; S Zanussi; P Paoli; E Vaccher; U Tirelli; M Giacca
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

5.  Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.

Authors:  H X Liao; B Etemad-Moghadam; D C Montefiori; Y Sun; J Sodroski; R M Scearce; R W Doms; J R Thomasch; S Robinson; N L Letvin; B F Haynes
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  A versatile vector for the production of pseudotyped viruses expressing gp120 antigens from different clades of primary HIV-1 isolates.

Authors:  Zheng Wang; Mingshun Zhang; Yan Wang; Yanmei Jiao; Lu Zhang; Lin Li; Zuhu Huang; Hao Wu; Jingyun Li; Shan Lu; Shixia Wang
Journal:  J Virol Methods       Date:  2010-10-27       Impact factor: 2.014

7.  A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses.

Authors:  Hua-Xin Liao; Laura L Sutherland; Shi-Mao Xia; Mary E Brock; Richard M Scearce; Stacie Vanleeuwen; S Munir Alam; Mildred McAdams; Eric A Weaver; Zenaido Camacho; Ben-Jiang Ma; Yingying Li; Julie M Decker; Gary J Nabel; David C Montefiori; Beatrice H Hahn; Bette T Korber; Feng Gao; Barton F Haynes
Journal:  Virology       Date:  2006-09-30       Impact factor: 3.616

8.  Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS.

Authors:  E L Delwart; H Pan; H W Sheppard; D Wolpert; A U Neumann; B Korber; J I Mullins
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

Review 9.  The Antibody Response against HIV-1.

Authors:  Julie Overbaugh; Lynn Morris
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

10.  Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.

Authors:  Mei-Yun Zhang; Vidita Choudhry; Igor A Sidorov; Vladimir Tenev; Bang K Vu; Anil Choudhary; Hong Lu; Gabriela M Stiegler; Hermann W D Katinger; Shibo Jiang; Christopher C Broder; Dimiter S Dimitrov
Journal:  J Immunol Methods       Date:  2006-10-16       Impact factor: 2.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.